Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYing–Hong Shi, Enxiao Li, Jianbing Wu et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 39